Answers are grounded in this paper and cite their sources.
Background The use of a vacuum erection device (VED) is an effective non-invasive therapy for Diabetes mellitus-induced erectile dysfunction (DMED); however, its molecular mechanism remains unclear. This study investigated whether VED exerts therapeutic effects against DMED by protecting corpus cavernosum smooth muscle cells (CCSMCs) via Piezo1/NFATc1 mechanotransduction. Methods Rats with streptozotocin-induced DMED were treated with VED alone or in combination with the Piezo1 agonist Yoda1 or inhibitor GsMTx4. Erectile function was evaluated by the ICP/MAP ratio, cavernosal apoptosis, and fibrosis. Primary rat CCSMCs subjected to cyclic mechanical stretching were used to mimic VED stimulation in vitro . The Piezo1/NFATc1 signalling axis was validated using pharmacological intervention, siRNA knockdown, calcium imaging, and transcriptomic analysis. Results VED treatment significantly improved erectile function and attenuated cavernosal apoptosis and fibrosis, concomitant with Piezo1 upregulation and NFATc1 dephosphorylation and nuclear translocation. Pharmacological activation of Piezo1 by Yoda1 recapitulated these protective effects, whereas Piezo1 inhibition or knockdown abrogated these benefits. NFATc1 knockdown further abolished the anti-apoptotic, anti-fibrotic and contractility-preserving effects induced by Piezo1 activation in CCSMCs. Conclusion VED ameliorates DMED by activating Piezo1, which drives Ca 2+ /calcineurin-dependent NFATc1 signaling to protect cavernosal smooth muscle, maintain its contractility, and suppress apoptosis and fibrosis. This Piezo1/NFATc1 mechanotransduction cascade represents a promising therapeutic target for DMED and provides a mechanistic rationale for developing related pharmacotherapies.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: